Braf-mutant metastatic non–small-cell lung cancer: Real world data from the Italian biomarker atlas database
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: BRAF mutations identify a small subgroup of patients (pts) with non-small cell lung cancer (NSCLC). Dabrafenib/trametinib (D/T) combination is associated with high response rates and durable anti-tumor activity in BRAF-V600-mutants. Several open questions still remain unanswered in clinical practice, including the efficacy of treatments based on clinical and molecular characteristics, the activity in patients with brain metastases, the optimal sequence with immunotherapy-based therapies. Here we present outcomes among advanced BRAF-mutant NSCLC patients from the Italian ATLAS registry. METHODS: Patients with metastatic BRAF-mutated NSCLC were included. Clinical-pathological features, treatment effectiveness and safety outcomes were retrospectively collected from the Italian real-world ATLAS registry. RESULTS: A total of 244 BRAF-mutated NSCLC pts were enrolled, including 70 % V600E mutations. The median PFS of first line D/T was 19.8 months (95 % CI: 10.7-29.0), with a 2-year OS rate of 65.4 % and a PFS2 of 6.6 months (95 % CI: 0-14.3). The activity of D/T differs among sex (mPFS was 13.6 mos and 25.3 mos and 2-yr OS rate were 54.9 % and 72.3 % in males and females, respectively) and smoking status (mPFS was 18.4 mos, 25.6 mos and 24 mos in never, former and current smokers, respectively). Concomitant MET amplification was associated with a shorter median PFS (mPFS was 13.6 mos vs. 44.3 mos with and without MET amplification respectively) in pts treated with D/T as 1st line. CONCLUSIONS: These data confirm the efficacy and safety of first line D/T in BRAF V600E-mutated pts in the real-world setting consistently with prior studies, suggesting a differential activity among key clinical-molecular subgroups.
Source: European Journal of Cancer
Authors: Claudio Sini, Alessandro Russo, Diego Cortinovis, Lucia Anna Muscarella, Marcello Tiseo, Emilio Bria, Salvatore Grisanti, Pierluigi Piovano, Antonello Veccia, Lorenzo Antonuzzo, Fabrizio Citarella, Sara Pilotto, Maria Lucia Reale, Daniele Pignataro, Elisa Roca, Lorenzo Calvetti, Pamela Pizzutilo, Gabriele Minuti, Giacomo Pelizzari, Greta Alì, Anna Bettini, Alberto Pavan, Diego Signorelli, Serena Ricciardi, Giulia Meoni, Concetta Sergi, Carlo Genova, Vieri Scotti, Tiziana Vavalà, Stefania Gori, Giulia Pasello, Paolo Pedrazzoli, Rita Chiari, Alessandro D’Aveni, Roberta Buosi, Luca Toschi, Hector Soto Parra, Lucio Buffoni, Brigida Stanzione, Cinzia Ortega, Cristina Zannori, Diana Giannarelli, Umberto Malapelle, Silvia Novello, Francesco Passiglia, Editta Baldini
Institutions: Humanitas University, University of Milano-Bicocca, Casa Sollievo della Sofferenza, University of Parma, Ospedale di Parma, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Azienda Ospedaliero-Universitaria Careggi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Ospedale Vito Fazzi, Azienda Sanitaria Locale di Asti, Ospedale P. Pederzoli – Casa di Cura Privata S.p.a., Azienda ULSS 8 Berica, Istituto Tumori Bari, Instituto Nazionale Tumori Regina Elena, Azienda sanitaria universitaria Friuli Centrale, University of Pisa, Azienda Ospedaliera Universitaria Pisana, Ospedale Papa Giovanni XXIII, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Azienda Ospedaliera San Camillo-Forlanini, Nuovo Ospedale San Giovanni di Dio, Ospedale Garibaldi, Ospedale Policlinico San Martino, University of Genoa, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Ospedale Sacro Cuore Don Calabria, University of Padua, Istituto Oncologico Veneto, University of Pavia, Policlinico San Matteo Fondazione, Azienda Socio Sanitaria Territoriale della Valle Olona, IRCCS Humanitas Research Hospital, Policlinico Universitario di Catania, Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco", Ospedale Humanitas Gradenigo, Centro di Riferimento Oncologico, Azienda Sanitaria Locale CN2, Azienda Ospedaliera S.Maria, Istituti di Ricovero e Cura a Carattere Scientifico, University of Naples Federico II, Ospedale San Luigi Gonzaga, University of Turin
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,270
OpenAlex ID: W7117127691